Sina Rashedi

Thrilled to present my research on the accuracy of Nation Language Processing Tools for Pulmonary Embolism Identification at the #AHA2024. My deepest thanks should go to Dr. @bbikdeli and Dr. Piazza for all their support. @AHAScience @BrighamResearch @BrighamFellows @harvardmed

Our new study is out in @AmericanHeartJ 🫀 In this multi-center study of 4,249 pts w/ severe AS: 📌42%, incl. 32% symptomatic AS, didn’t undergo AVR; rates impacted by provider specialty at diagnosis 📌 Gaps more pronounced in LF-LG AS 📌 Black pts less likely to receive AVR…

📢 Check out my new invited editorial in @ESC_Journals #EHJQCCO on whether TAVI closes the survival gap with the general population. 💡5-year survival matches the general population—better in ≥85y, but gaps remain in <80y. 🔗 doi.org/10.1093/ehjqcc… #TAVI #TAVR #MedTwitter

Ultraslow/slow low-dose thrombolysis is a new era in the treatment of acute MPVT, but larger data is needed for longterm benefit 🙏 @yeganehpasebani, Zahra, Arezo, @kasra_mdz @AliRafati_ for their 3y effort and commitment and Prof De Caterina for his constant mentorship

Substantial proportion of MPVT 💉 w/ ultraslow/slow low-dose thrombolysis remains thrombosis free after 3y. But, nearly 1/4 experienced rethrombosis challenging current guidelines which do not promote routine f/u imaging in such patients shorturl.at/CLBtF @ThrombosisRese1

Check out our recent paper on #AF catheter ablation in cardiac #amyloidosis and #sarcoidosis vs. matched reference groups ⬆️ Low voltage areas ⬆️ Non-PV triggers (AF & focal AT) ⬆️ LA flutters @PennEPFellows @PennCardiology #Epeeps

📜 Thrilled to see our latest work on #PE and #ICD-10 codes led by the ⭐️ @SinaRsh published @isth! The combination of Present-On-Admission indicators with #ICD-10 codes improves accuracy of #PE identification using electronic health records! thieme-connect.com/products/ejour…

#2 One of my @ISTH presentations was simultaneously published! 📄 thieme-connect.com/products/ejour… > Incorporating Present-On-Admission indicators into ICD-10 codes improves accuracy of PE identification from claims data Thanks to the collaborators & mentors! #Thrombosis #HealthData

#1 This week, I had the opportunity to deliver my first oral presentation and present two posters at @ISTH! I’m deeply grateful for the support of my mentors @GregoryPiazza4 and @bbikdeli, and for the opportunity to share our work and learn from experts #ISTH2025 #CardioResearch

Just won Intern of the Year! 🏆 Grateful for the recognition and all the support along the way 🙌 Excited for what’s next! 🚀 #InternOfTheYear #Grateful #HardWorkPaysOff

Excited to share our new paper in JACC: Advances! ✨📄 We reviewed how #MachineLearning can boost polygenic risk scores for better CVD prediction—across 1M+ participants. Big thanks to @sina_kazemian for leading this journey! 🫀 #Cardiology #Genomics

Cobra Trial: #apixaban safer than #rivaroxaban for venous #thrombosis treatment #ISTH2025 ⁦@AnticoagForum⁩ ⁦@Vasculearn⁩ ⁦@PERTConsortium⁩ ⁦@thrombosisday⁩ ⁦@ThrombosisCan⁩ ⁦@canvector⁩ ⁦@EuropeanTHA⁩ ⁦@CMichaelGibson⁩ ⁦

📄 New publication in European Heart Journal Open: “Age and sex differences in vasovagal syncope”. In ~2,000 patients, we examined how age and sex shape triggers, symptoms, and HUTT results. @MasihTajdini 🔗doi.org/10.1093/ehjope… #Cardiology #Syncope #EHJOpen

Antiplatelet or anticoagulant? The new ACS guideline decodes the chaos with clarity. A must-read roadmap for frontline care 🧭 jacc.org/doi/10.1016/j.… #JACC #cvACS #ClinicalGuidelines @Drroxmehran @djc795 @bbikdeli @hmkyale

💜 How we talk about blood clots matters. 💜 🏥 The VTE Communication Guide was created to help clinicians navigate the complex conversations that follow a venous thromboembolism (VTE) diagnosis from risk and treatment to emotions and uncertainty. ❤️ This project brings…

🚨🚨Now there is a full issue of @JACCJournals dedicated to the new @ACCinTouch @AHAScience guideline for #ACS!! 👇 jacc.org/toc/jacc/curre… @SVRaoMD @DrM_ODonoghue @hmkyale

We summarized the guideline recs for #anticoagulant& #antiplatelettherapy in ACS & compared them w prior recs in @ACCinTouch @AHAScience & @escardio guidelines. 🙏🙏 Writing Committee and also a great team who made this summary possible 👇👇: jacc.org/doi/10.1016/j.…

Need to do better for #PE risk stratification, beyond reductionist models. In an @ESC_Journals #EHJ paper we show that a multimarker calculator🌡️outperforms the ESC model. Great work by @DJC6998 @mmonrealriete et al #RIETE! Honored to be a part of it 👇: tinyurl.com/trpmzbrd

Honored to receive Honorable Mention at #SIIM25 for our work on de-identifying medical reports on edge devices using SLMs 🏆 Congrats to @theodapamede for winning Best Paper with his CV risk prediction from mammograms! 👏 Grateful to my mentors @Slowvak and @judywawira 🙏🏻

Exciting day with more obicetrapib data for at ⁦⁦@society_eas⁩ with publications in ⁦@NEJM⁩ and ⁦@TheLancet⁩ ⁦@JohnKastelein⁩ ⁦@ProfKausikRay⁩ ⁦@mdavidsonmd⁩ ⁦@ajnelson⁩ ⁦@julie_butters⁩ ⁦@MonashVHI⁩ ⁦@NewAmsPharma⁩

🚨 New Publication Alert! 🚨 Thrilled to share our latest work in Immunity (June 2025) as a coauthor: 🧬 "Somatic hypermutation unlocks antibody specificities beyond the primary repertoire" 🔍 Key Highlights: • 💡 Non-cognate B cells can enter germinal centers & develop de…